Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.

Oscarsson J, Huhn M, Jiang Y, Gause-Nilsson I, Wiviott SD, Moura FA, Wilding JPH, Cernea S, Van Gaal L, Cahn A, Bhatt DL, Johansson PA, Sjöström CD

Open source

DOI: 10.1111/dom.70820
Published: 2026 Jul
Container: Diabetes, obesity & metabolism
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/dom.70820,
  title = {Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.},
  author = {Oscarsson J and Huhn M and Jiang Y and Gause-Nilsson I and Wiviott SD and Moura FA and Wilding JPH and Cernea S and Van Gaal L and Cahn A and Bhatt DL and Johansson PA and Sjöström CD},
  year = {2026},
  journal = {Diabetes, obesity \& metabolism},
  doi = {10.1111/dom.70820},
  url = {https://doi.org/10.1111/dom.70820}
}

RIS

TY  - JOUR
TI  - Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.
AU  - Oscarsson J
AU  - Huhn M
AU  - Jiang Y
AU  - Gause-Nilsson I
AU  - Wiviott SD
AU  - Moura FA
AU  - Wilding JPH
AU  - Cernea S
AU  - Van Gaal L
AU  - Cahn A
AU  - Bhatt DL
AU  - Johansson PA
AU  - Sjöström CD
PY  - 2026
JO  - Diabetes, obesity & metabolism
DO  - 10.1111/dom.70820
UR  - https://doi.org/10.1111/dom.70820
ER  -

APA

J, O., M, H., Y, J., I, G., SD, W., FA, M., JPH, W., S, C., L, V. G., A, C., DL, B., PA, J., & CD, S. (2026). Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70820

Source records

pubmed · retrieved 2026-09-26T10:24:57.364Z